As of June 17, 2025, Gene One Life Science Inc (011000.KS) reports a ROE (Return on Equity) of -56.70%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Gene One Life Science Inc's ROE (Return on Equity)
Over recent years, Gene One Life Science Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -56.70% |
| 2023-12-31 | -69.75% |
| 2022-12-31 | -21.02% |
| 2021-12-31 | -7.69% |
| 2020-12-31 | -18.93% |
This slight upward trend highlights how Gene One Life Science Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Gene One Life Science Inc's ROE (Return on Equity) to Peers
To better understand Gene One Life Science Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Gene One Life Science Inc (011000.KS) | -56.70% |
| L&C Bio Co Ltd (290650.KQ) | 49.61% |
| PharmaResearch Co Ltd (214450.KQ) | 17.06% |
| Isu Abxis Co Ltd (086890.KQ) | 14.59% |
| Hans Biomed Corp (042520.KQ) | 13.47% |
| BNC Korea Co Ltd (256840.KQ) | 12.26% |
Compared to its competitors, Gene One Life Science Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.